Eli Lilly and Novo Nordisk Compete in Obesity Drug Market, Novo Nordisk Faces Pricing Test

Eli Lilly has taken the lead in the obesity drug race against Novo Nordisk, whose GLP-1 pill momentum is now facing a pricing test, according to a leading bank.